RADIOLABELED PROGASTRIN IN CANCER DIAGNOSIS Russian patent published in 2024 - IPC C07K14/595 A61K51/08 A61K103/00 A61B8/13 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a compound or a pharmaceutically acceptable salt thereof for cancer imaging. The proposed compound contains: a progastrin group having the sequence of the following SEQ ID NO: 1, and a chelating moiety, wherein the chelating moiety is a bifunctional chelator selected from the following list: NODAGA (1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid), NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), p-SCN-Bn-NOTA, p-SCN-Bn-PCTA, p-SCN-Bn-oxo-DO3A, desferrioxamine-p-SCN, DTPA (diethylenetriaminepentaacetic acid) and TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid). The said chelating group is associated with a radioactive isotope. The progastrin moiety and the chelating moiety are covalently linked. Also the following is proposed: a method of producing the said compound, a method of imaging of one or more cancer cells, organs or tissues in a subject, a method of determining the location of cancer in a subject, a pharmaceutical composition and a kit for imaging one or more cancer cells containing the said compound.

EFFECT: compounds of the invention are capable of binding to cancer cells in vivo, thereby providing imaging of the said cancer, which is particularly useful for identifying the location of the cancer.

12 cl, 4 dwg, 3 tbl